Global Blood Therapeutics

2 Biotechs With Approaching Drug Approvals
2 Biotechs With Approaching Drug Approvals
Motley Fool
drug approvals
drug launches
FDA
voxelotor
Global Blood Therapeutics
Immunomedics
sacituzumab govitecan
Flag link:
Why Global Blood Therapeutics Stock Jumped 10.9% Today
Why Global Blood Therapeutics Stock Jumped 10.9% Today
Motley Fool
Global Blood Therapeutics
FDA
voxelotor
sickle cell disease
Flag link:
GBT sickle cell trial hits endpoint ahead of NDA filing
GBT sickle cell trial hits endpoint ahead of NDA filing
Fierce Biotech
Global Blood Therapeutics
sickle cell disease
FDA
voxelotor
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
[audio+transcript] 6 Biotech Stocks to Watch Now
[audio+transcript] 6 Biotech Stocks to Watch Now
Motley Fool
Biogen
Bluebird Bio
Global Blood Therapeutics
Aimmune Therapeutics
Vertex Pharmaceuticals
Sarepta Therapeutics
Flag link:
Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval
Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval
EP Vantage
Vertex Pharma
cystic fibrosis
Symdeko
Kalydeco
Global Blood Therapeutics
voxelotor
sickle cell disease
Flag link:
Once lauded for its clinical success, Roche casts off cardio program inclacumab for a mere $2M to Global Blood Therapeutics
Once lauded for its clinical success, Roche casts off cardio program inclacumab for a mere $2M to Global Blood Therapeutics
Endpoints
Roche
inclacumab
Global Blood Therapeutics
Flag link:
GBT touts positive sickle cell trial, but shares yo-yo as investors mull data
GBT touts positive sickle cell trial, but shares yo-yo as investors mull data
Fierce Biotech
Global Blood Therapeutics
sickle cell disease
voxelotor
clinical trials
Flag link:
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
Flag link:
Novo Nordisk in Talks to Buy Global Blood Therapeutics
Novo Nordisk in Talks to Buy Global Blood Therapeutics
Investopedia
Novo Nordisk
M&A
Global Blood Therapeutics
Flag link:
Shares in Global Blood climb after positive study results for experimental sickle cell treatment
Shares in Global Blood climb after positive study results for experimental sickle cell treatment
First Word Pharma
Global Blood Therapeutics
GBT440
sickle cell disease
Flag link:
10 Biotechs Short Sellers Are Betting Against
10 Biotechs Short Sellers Are Betting Against
Yahoo/Benzinga
biotech
Global Blood Therapeutics
Clovis Oncology
Epizyme
Bluebird Bio
Puma Biotechnology
Tokai
MannKind
Myriad Genetics
Orexigan
KaloBios
Flag link:
The Big News For Sickle Cell Anemia Is Not Gene Therapy
The Big News For Sickle Cell Anemia Is Not Gene Therapy
Forbes
gene therapy
sickle cell disease
Global Blood Therapeutics
GBT440
Flag link:
ASH scorecard: AbbVie rides high, GBT slips and Celgene settles in
ASH scorecard: AbbVie rides high, GBT slips and Celgene settles in
Fierce Biotech
AbbVie
Celgene
Roche
Global Blood Therapeutics
Flag link:
Sickle cell biotech GBT banks $120M in an above-range IPO
Sickle cell biotech GBT banks $120M in an above-range IPO
Fierce Biotech
sickle cell disease
IPOs
Global Blood Therapeutics
Flag link: